Retrospective study of usefulness and safety of ustekinumab and vedolizumab in patients with inflammatory bowel diseases

Retrospective study of usefulness and safety of ustekinumab and vedolizumab in patients with inflammatory bowel diseases - UV in IBD Retrospective Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050116

Enrollment

300

Registered

2023-04-01

Start date

2023-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients treated with ustekinumab and / or vedolizumab

Exclusion criteria

Exclusion criteria: 1. patients who access us to refuse entry in this study 2. patienst without precise clinical record

Design outcomes

Primary

Measure	Time frame
persistence of UST and VED until one year	—

Secondary

Measure	Time frame
1. proportion of patients in clinical remission until half a year and a year 2. proportion of patients in clinical response until half a year and a year 3. proportion of patients in steroid-free clinical remission until half a year and a year 4. Rates of negative fecal calprotectin until half a year and a year 5. time-course changes of inflammatory markers 6. proportion of patients in clinical remission after chages of treatment 7. proportion of patients in clinical response after chages of treatment 8. safety during observationa period	—

Measure

Time frame

1. proportion of patients in clinical remission until half a year and a year 2. proportion of patients in clinical response until half a year and a year 3. proportion of patients in steroid-free clinical remission until half a year and a year 4. Rates of negative fecal calprotectin until half a year and a year 5. time-course changes of inflammatory markers 6. proportion of patients in clinical remission after chages of treatment 7. proportion of patients in clinical response after chages of treatment 8. safety during observationa period

—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp049-228-3564

Outcome results